Nasopharyngeal Carcinoma

Through a comprehensive and systematic search of the best available evidence, the Neoplastic Diseases Task Force developed 20 recommendations on screening and risk factor assessment for 10 specific questions on neoplastic diseases. These recommendations serve as guidance on screening neoplastic diseases at the primary care level.

PD-1/PD-L1 combined with LAG-3 inhibitors demonstrates higher response rates, but the survival outcomes remain unclear. Further, patients with NPC, Chinese population, and individuals aged < 60 years may potentially benefit from the combination therapy.

A robust five-gene signature was established and validated for prognostic stratification of locally advanced NPC. Reproducibility across transcriptomic platforms and biological relevance support clinical application to guide personalized treatment.

Our findings suggest that CD44 may act as a key regulator linking iron metabolism and immune modulation in EBV-associated NPC. Although direct iron measurements were not performed, the observed associations with reduced CD8⁺ T-cell infiltration are consistent with a potential role of CD44 in shaping an immune-restricted tumor microenvironment. These results provide integrative evidence of a CD44-iron-immune axis in a Tunisian NPC cohort and highlight CD44 as a potential prognostic biomarker and therapeutic target.

Interference with miR-4429 reversed the inhibitory effects of circFOXP1 silencing on proliferation, migration and invasion of nasopharyngeal carcinoma cells (P < 0.05). Inhibition of circFOXP1 expression can attenuate the proliferation, migration and invasion of nasopharyngeal carcinoma 6-10B cells by targeting miR-4429.

In NPC, IGF1 serves to suppress tumor progression, inhibiting malignant phenotypes and aerobic glycolysis through the upregulation of PGM5. The IGF1-PGM5 axis represents a novel metabolic regulatory pathway that may warrant further investigation as a potential therapeutic target for NPC intervention.

P=N/A, N=50, Not yet recruiting, National University Hospital, Singapore

Through an integrated workflow combining proteomic screening, machine learning prioritization, and multi-stage ELISA validation, we identified SULT1A3 as a candidate serum-based biomarker for early detection of NPC. Preliminary findings suggest that SULT1A3 may have potential utility in clinical screening, though further validation in independent, multi‑center cohorts is required.

In summary, we established a novel fatty-acid-metabolism-related prognostic model for assessing the prognosis and potential immunotherapy response of NPC patients, as well as for characterizing the immunological features of the tumor microenvironment (TME). Furthermore, ABCC1 emerged as a promising prognostic biomarker associated with immunotherapeutic responsiveness in NPC, warranting further validation.

These pro-tumorigenic and pro-autophagic effects were consistently observed in vivo. In conclusion, MALAT1 promotes autophagy by sequestering miR-28-5p to upregulate IGF1R in NPC, providing a novel mechanistic insight and a potential therapeutic target.

SLC44A4 overexpression also increased sensitivity to DNA-damaging agents, including temozolomide, doxorubicin, cisplatin, olaparib, and etoposide, while decreasing sensitivity to 5-fluorouracil. Together, these findings identify SLC44A4 as a potential tumor-suppressive factor in NPC and suggest that SLC44A4 may serve as a biomarker for metabolic state, B-cell/TLS-associated immune features, and vulnerability to DNA damage-based therapies.